3 recruiting, 1 not yet recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow HDM1005 2: new trials by email Literature Review of HDM1005 2 trials Research Report on HDM1005 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor HDM1005 1, HDM1005 2, Mazdutide - Type 2 Diabetes | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 912 | 2026-03-27 | 2026-02-18 |
| A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone HDM1005 1, HDM1005 2, HDM1005 injection or placebo - Type 2 Diabetes | Phase 3 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 240 | 2026-02-24 | 2026-02-09 |
| Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes HDM1005 1, HDM1005 2, Placebo - Obesity & Overweight | Phase 3 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 825 | 2025-10-14 | 2025-12-12 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin HDM1005 1, HDM1005 2, HDM1005 3 - Type 2 Diabetes | Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 216 | 2025-04-30 | 2025-08-17 |
Diabetes Mellitus, Type 2 (3) · Obesity (1) · Overweight (1)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (4)
China (4)
Linong Ji (1) · Xiaoying Li (1)